Achieve Life Sciences (ACHV) Stock Price, News & Analysis

Company Overview

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.

Key Stats

• Today's Range: $1.95 to $2.14
• 50-Day Range: $1.98 to $3.42
• 52-Week Range: $1.84 to $5.59
• Volume: 260,158 shs
• Average Volume: 182,531 shs
• Market Capitalization: $69.02 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $14.33
• Consensus Rating: Strong Buy

Achieve Life Sciences Stock Analysis - MarketRank™

Achieve Life Sciences scored higher than 36% of companies evaluated by MarketBeat, and ranked 564th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Strong Buy

Consensus Rating

Achieve Life Sciences has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Achieve Life Sciences has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Achieve Life Sciences are expected to grow in the coming year, from ($1.17) to ($1.16) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Achieve Life Sciences is -1.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Achieve Life Sciences is -1.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.52% of the float of Achieve Life Sciences has been sold short.

Short Interest Ratio / Days to Cover

Achieve Life Sciences has a short interest ratio ("days to cover") of 11.9, which indicates bearish sentiment.

Change versus previous month

Short interest in Achieve Life Sciences has recently decreased by 5.28%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Achieve Life Sciences does not currently pay a dividend.

Dividend Growth

Achieve Life Sciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

8.52% of the float of Achieve Life Sciences has been sold short.

Short Interest Ratio / Days to Cover

Achieve Life Sciences has a short interest ratio ("days to cover") of 11.9, which indicates bearish sentiment.

Change versus previous month

Short interest in Achieve Life Sciences has recently decreased by 5.28%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 2 people have searched for ACHV on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Achieve Life Sciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $28,900.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 2.00% of the stock of Achieve Life Sciences is held by insiders.

Percentage Held by Institutions

Only 33.52% of the stock of Achieve Life Sciences is held by institutions.

ACHV Stock Analysis - Frequently Asked Questions

How have ACHV shares performed this year?

Achieve Life Sciences' stock was trading at $3.52 at the start of the year. Since then, ACHV shares have decreased by 43.5% and is now trading at $1.99.
View the best growth stocks for 2025 here.

How were Achieve Life Sciences' earnings last quarter?

Achieve Life Sciences, Inc. (NASDAQ:ACHV) announced its quarterly earnings results on Tuesday, March, 11th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.30) by $0.06.
Read the conference call transcript.

When did Achieve Life Sciences' stock split?

Achieve Life Sciences shares reverse split on Friday, July 31st 2020. The 1-20 reverse split was announced on Thursday, July 30th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 30th 2020. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

How do I buy shares of Achieve Life Sciences?

Shares of ACHV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Achieve Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Achieve Life Sciences investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Meta Platforms (META), Moderna (MRNA), Netflix (NFLX) and Visa (V).

Company Calendar

• Last Earnings: 3/11/2025
• Today: 4/18/2025
• Next Earnings (Estimated): 5/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Diagnostic substances
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ACHV
• CIK: 949858
• Web: achievelifesciences.com
• Phone: (604) 210-2217
• Fax: 425-686-1600
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $14.33
• High Stock Price Target: $20.00
• Low Stock Price Target: $11.00
• Potential Upside/Downside: +620.3%
• Consensus Rating: Strong Buy
• Rating Score (0-4): 3.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.23)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-29,820,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -108.30%
• Return on Assets: -65.20%

Debt

• Debt-to-Equity Ratio: 0.31
• Current Ratio: 6.78
• Quick Ratio: 6.78

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.07) per share
• Price / Book: -28.43

Miscellaneous

• Outstanding Shares: 34,685,000
• Free Float: 33,702,000
• Market Cap: $69.02 million
• Optionable: Optionable
• Beta: 1.59